Literature DB >> 2971677

Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

A S Lau1, S E Read, B R Williams.   

Abstract

Interferons (IFN) elicit antiviral and antineoplastic activities by binding to specific receptors on the cell surface. In evaluating the role of IFN as therapeutic agents in AIDS, we investigated the expression of IFN alpha and gamma receptors on peripheral blood mononuclear cells (PBM) from patients with AIDS, ARC, and heterosexual control subjects using radioiodinated IFN alpha 2 and IFN gamma. The binding characteristics of the 125I-IFN alpha and gamma to PBM were analyzed to determine receptor numbers and dissociation constants. PBM from controls expressed 498 +/- 247 IFN alpha receptor sites/cell (n = 17). However, eight patients with ARC and seven patients with AIDS had a mean number of IFN alpha receptor/cell of 286 +/- 235 (P less than 0.05) and 92 +/- 88 (P less than 0.001), respectively. This was consistent with elevated levels of serum acid-labile IFN alpha and cellular 2-5A synthetase activity in patients. Treatment of PBM from the AIDS patients with exogenous IFN alpha in vitro resulted in minimal 2-5A synthetase induction in comparison to controls. In contrast, the expression of IFN gamma receptors in ARC (n = 5) and AIDS (n = 4) patients remained normal. Thus the decrease in IFN alpha receptor expression and consequent hyporesponsiveness to IFN alpha raises the question of the usefulness of IFN alpha therapy in end-stage AIDS. The normal expression of IFN gamma receptors in AIDS patients suggests that IFN gamma may prove useful in attempts to provide immune reconstitution.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2971677      PMCID: PMC442699          DOI: 10.1172/JCI113746

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  37 in total

Review 1.  NIH conference. Acquired immunodeficiency syndrome: epidemiologic, clinical, immunologic, and therapeutic considerations.

Authors:  A S Fauci; A M Macher; D L Longo; H C Lane; A H Rook; H Masur; E P Gelmann
Journal:  Ann Intern Med       Date:  1984-01       Impact factor: 25.391

2.  Severe acquired immune deficiency syndrome in male homosexuals: diminished capacity to make interferon-alpha in vitro associated with severe opportunistic infections.

Authors:  C Lopez; P A Fitzgerald; F P Siegal
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

3.  Decreased expression of human class II antigens on monocytes from patients with acquired immune deficiency syndrome. Increased expression with interferon-gamma.

Authors:  W Heagy; V E Kelley; T B Strom; K Mayer; H M Shapiro; R Mandel; R Finberg
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

Review 4.  Immunologic abnormalities in the acquired immunodeficiency syndrome.

Authors:  H C Lane; A S Fauci
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

5.  Elevated levels of interferon-induced 2'-5' oligoadenylate synthetase in generalized persistent lymphadenopathy and the acquired immunodeficiency syndrome.

Authors:  S E Read; B R Williams; R A Coates; W K Evans; M M Fanning; M B Garvey; F A Shepherd
Journal:  J Infect Dis       Date:  1985-09       Impact factor: 5.226

6.  Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters.

Authors:  E P Gelmann; O T Preble; R Steis; H C Lane; A H Rook; M Wesley; J Jacob; A Fauci; H Masur; D Longo
Journal:  Am J Med       Date:  1985-05       Impact factor: 4.965

7.  Disseminated Kaposi's sarcoma in homosexual men.

Authors:  A E Friedman-Kien; L J Laubenstein; P Rubinstein; E Buimovici-Klein; M Marmor; R Stahl; I Spigland; K S Kim; S Zolla-Pazner
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

8.  Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders.

Authors:  J L Fahey; H Prince; M Weaver; J Groopman; B Visscher; K Schwartz; R Detels
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome.

Authors:  H C Lane; H Masur; L C Edgar; G Whalen; A H Rook; A S Fauci
Journal:  N Engl J Med       Date:  1983-08-25       Impact factor: 91.245

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  9 in total

1.  Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens.

Authors:  V Vieillard; I Cremer; E Lauret; W Rozenbaum; P Debré; B Autran; E De Maeyer
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

2.  Endotoxin induction of tumor necrosis factor is enhanced by acid-labile interferon-alpha in acquired immunodeficiency syndrome.

Authors:  A S Lau; J F Livesey
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

3.  Desensitization to type I interferon in HIV-1 infection correlates with markers of immune activation and disease progression.

Authors:  Gareth A D Hardy; Scott F Sieg; Benigno Rodriguez; Wei Jiang; Robert Asaad; Michael M Lederman; Clifford V Harding
Journal:  Blood       Date:  2009-03-19       Impact factor: 22.113

4.  Systemic tumor necrosis factor-alpha production in experimental colitis.

Authors:  D R Mack; A S Lau; P M Sherman
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

5.  The relationship between simian immunodeficiency virus RNA levels and the mRNA levels of alpha/beta interferons (IFN-alpha/beta) and IFN-alpha/beta-inducible Mx in lymphoid tissues of rhesus macaques during acute and chronic infection.

Authors:  Kristina Abel; Michelle J Alegria-Hartman; Kristina Rothaeusler; Marta Marthas; Christopher J Miller
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Preservation of monocyte effector functions against Mycobacterium avium-M. intracellulare in patients with AIDS.

Authors:  J L Johnson; H Shiratsuchi; H Toba; J J Ellner
Journal:  Infect Immun       Date:  1991-10       Impact factor: 3.441

Review 7.  Type I interferon and HIV: Subtle balance between antiviral activity, immunopathogenesis and the microbiome.

Authors:  Carolina Scagnolari; Guido Antonelli
Journal:  Cytokine Growth Factor Rev       Date:  2018-03-16       Impact factor: 7.638

8.  Low autocrine interferon beta production as a gene therapy approach for AIDS: Infusion of interferon beta-engineered lymphocytes in macaques chronically infected with SIVmac251.

Authors:  Wilfried Gay; Evelyne Lauret; Bertrand Boson; Jérome Larghero; Franck Matheux; Sophie Peyramaure; Véronique Rousseau; Dominique Dormont; Edward De Maeyer; Roger Le Grand
Journal:  Retrovirology       Date:  2004-09-25       Impact factor: 4.602

Review 9.  Biology of natural killer cells.

Authors:  G Trinchieri
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.